Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Crystal Field Theory - Octahedral Complexes02:58

Crystal Field Theory - Octahedral Complexes

31.0K
Crystal Field Theory
To explain the observed behavior of transition metal complexes (such as colors), a model involving electrostatic interactions between the electrons from the ligands and the electrons in the unhybridized d orbitals of the central metal atom has been developed. This electrostatic model is crystal field theory (CFT). It helps to understand, interpret, and predict the colors, magnetic behavior, and some structures of coordination compounds of transition metals.
CFT focuses on...
31.0K
Crystal Field Theory - Tetrahedral and Square Planar Complexes02:46

Crystal Field Theory - Tetrahedral and Square Planar Complexes

48.6K
Tetrahedral Complexes
Crystal field theory (CFT) is applicable to molecules in geometries other than octahedral. In octahedral complexes, the lobes of the dx2−y2 and dz2 orbitals point directly at the ligands. For tetrahedral complexes, the d orbitals remain in place, but with only four ligands located between the axes. None of the orbitals points directly at the tetrahedral ligands. However, the dx2−y2 and dz2 orbitals (along the Cartesian axes) overlap with the ligands less than the dxy,...
48.6K
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

163
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
163
Indicators02:39

Indicators

61.1K
Certain organic substances change color in dilute solution when the hydronium ion concentration reaches a particular value. For example, phenolphthalein is a colorless substance in any aqueous solution with a hydronium ion concentration greater than 5.0 × 10−9 M (pH < 8.3). In more basic solutions where the hydronium ion concentration is less than 5.0 × 10−9 M (pH > 8.3), it is red or pink. Substances such as phenolphthalein, which can be used to determine the pH of a solution, are...
61.1K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.3K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.3K
The Atomic Theory of Matter02:59

The Atomic Theory of Matter

129.6K
The earliest recorded discussion of the basic structure of matter comes from ancient Greek philosophers. Leucippus and Democritus argued that all matter was composed of small, finite particles that they called atomos, meaning “indivisible.” Later, Aristotle and others came to the conclusion that matter consisted of various combinations of the four “elements” — fire, earth, air, and water — and could be infinitely divided. Interestingly, these philosophers...
129.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

American Indians' Growing Presence In The Health Professions.

Health affairs (Project Hope)·2021
Same author

Community health workers improve outcomes, reduce costs.

Managed care (Langhorne, Pa.)·2019
Same author

Financial incentives encourage pregnant women to quit smoking.

Managed care (Langhorne, Pa.)·2019
Same author

Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: A systematic review and meta-analysis.

Journal of psychiatric research·2018
Same author

Blood Sugar Control Limbo: How Low To Go?

Managed care (Langhorne, Pa.)·2018
Same author

Purchasers to Insurers: Standardize Your ACO Measures.

Managed care (Langhorne, Pa.)·2018

Related Experiment Video

Updated: Feb 10, 2026

Author Spotlight: Segmentation and VR for Advanced Neurovascular Interventions
06:18

Author Spotlight: Segmentation and VR for Advanced Neurovascular Interventions

Published on: April 5, 2024

1.6K

Indication-specific Drug Pricing - Simple in Theory, Complex in Reality.

Sarah Kwon

    Managed Care (Langhorne, Pa.)
    |May 16, 2018
    PubMed
    Summary

    Varying drug prices by indication offers a value-based strategy in oncology. However, administrative costs and regulatory hurdles may impede its benefits.

    Area of Science:

    • Health economics
    • Oncology
    • Pharmaceutical policy

    Background:

    • Multiple indications for oncology drugs are increasingly common.
    • Value-based pricing strategies are being explored in healthcare.

    Purpose of the Study:

    • To evaluate the potential of varying drug prices by indication in oncology.
    • To assess the feasibility of this strategy considering costs and regulations.

    Main Methods:

    • Analysis of potential benefits of indication-specific drug pricing.
    • Examination of administrative cost implications.
    • Review of legal and regulatory barriers.

    Main Results:

    • Indication-based pricing could align drug costs with clinical value in oncology.
    Keywords:
    Drug CostsHealth Care CostsPharmaceutical EconomicsPharmacoeconomics

    More Related Videos

    Mixed Reality Technology and Three-Dimensional Printing in Teaching: Heart Anatomy as an Example
    06:18

    Mixed Reality Technology and Three-Dimensional Printing in Teaching: Heart Anatomy as an Example

    Published on: April 18, 2025

    837
    Validation of a Mouse Model to Disrupt LINC Complexes in a Cell-specific Manner
    09:02

    Validation of a Mouse Model to Disrupt LINC Complexes in a Cell-specific Manner

    Published on: December 10, 2015

    7.8K

    Related Experiment Videos

    Last Updated: Feb 10, 2026

    Author Spotlight: Segmentation and VR for Advanced Neurovascular Interventions
    06:18

    Author Spotlight: Segmentation and VR for Advanced Neurovascular Interventions

    Published on: April 5, 2024

    1.6K
    Mixed Reality Technology and Three-Dimensional Printing in Teaching: Heart Anatomy as an Example
    06:18

    Mixed Reality Technology and Three-Dimensional Printing in Teaching: Heart Anatomy as an Example

    Published on: April 18, 2025

    837
    Validation of a Mouse Model to Disrupt LINC Complexes in a Cell-specific Manner
    09:02

    Validation of a Mouse Model to Disrupt LINC Complexes in a Cell-specific Manner

    Published on: December 10, 2015

    7.8K
  • Significant administrative costs may arise from implementing such a system.
  • Legal and regulatory challenges could hinder adoption.

    • Conclusions:

    • Varying drug prices by indication presents a potential value-based approach in oncology.
    • The economic and regulatory landscape requires careful consideration for successful implementation.